Friday, March 13, 2026
  • Login
FNGR Podcast
Subscribe to the podcast
  • Apple PodcastsApple Podcasts
  • SpotifySpotify
  • Google PodcastsGoogle Podcasts
  • AnchorAnchor
  • Home
  • Guests
  • Playlist of the Week
  • Yo Da Love Expert
No Result
View All Result
  • Home
  • Guests
  • Playlist of the Week
  • Yo Da Love Expert
Subscribe
No Result
View All Result
FNGR Podcast
Subscribe
  • Apple PodcastsApple Podcasts
  • SpotifySpotify
  • Google PlayGoogle Play
  • AnchorAnchor

Merck Agrees to Allow Other Drug Makers to Produce Its Potentially Game-Changing COVID-19 Pill

by FNGR Staff
October 27, 2021
0
16
SHARES
40
VIEWS
Share on FacebookShare on Twitter
complexcon logo

ComplexCon returns to Long Beach Nov. 6 – 7 with hosts J. Balvin and Kristen Noel Crawley, performances by A$AP Rocky and Turnstile, and more shopping and drops.

Secure your spot while tickets last!

Merck, the New Jersey-headquartered pharmaceutical company, has announced an agreement under which other drug makers will be able to produce a COVID-19 pill that’s previously been touted as a potential game-changer for the pandemic era.

A rep for the Medicines Patent Pool (MPP), as reported by the Associated Press on Wednesday, said that a voluntary licensing agreement had been signed for the pill with Merck and collaborator Ridgeback Biotherapeutics. In short, the agreement means the MPP can grant additional licenses to other companies approved to make the drug, the official name for which is molnupiravir.

For as long as the World Health Organization considers the pandemic to be a worldwide emergency situation, neither drug company will receive royalties. Frank Clyburn, executive vice president and president of Human Health at Merck, said in a statement released Wednesday that this latest move will further their approach to providing “broad, affordable access” to the medicine.

“Merck’s mission to save and improve lives is a truly global commitment,’ Clyburn said. “This agreement with MPP is another important element in our multi-faceted strategy to accelerate broad, affordable access to molnupiravir, if approved or authorized, for patients no matter where they live, including in countries where governments face greater challenges to finance healthcare.”

Previously, Merck and partner Ridgeback Biotherapeutics shared a breakdown of the “compelling results” seen in clinical trials for the oral COVId-19 treatment. The medicine is said to significantly reduce the risk of hospitalization or death, with Merck CEO Robert M. Davis previously sharing his assessment that molnupiravir could become an “important medicine” moving forward.

Related Stories

STORY CONTINUES BELOW

Speaking of a global pandemic that’s claimed the lives of millions, getting vaccinated—if you haven’t (wisely) already done so—is easy here in the U.S.. Just click here to find an appointment near you.

Related Posts

Meet These Extraordinary FOOD HEROES in Our New Documentary Series
News

Meet These Extraordinary FOOD HEROES in Our New Documentary Series

January 30, 2024
Celebrities’ Favorite Snacks From Around the World | Snacked
News

Celebrities’ Favorite Snacks From Around the World | Snacked

December 26, 2023
Steve-O Is Extra Naughty For the Hot Ones Holiday Extravaganza | Hot Ones
News

Steve-O Is Extra Naughty For the Hot Ones Holiday Extravaganza | Hot Ones

December 21, 2023
LEGENDARY Arthur Ave Italian Food Tour + Babish Makes Spaghetti all’ Assassina! | Heat Eaters
News

LEGENDARY Arthur Ave Italian Food Tour + Babish Makes Spaghetti all’ Assassina! | Heat Eaters

December 18, 2023
Keith Lee Rates NY Chop Cheeses, Talks Cardi B Co-Sign & How To Build TikTok | 360 with Speedy
News

Keith Lee Rates NY Chop Cheeses, Talks Cardi B Co-Sign & How To Build TikTok | 360 with Speedy

December 12, 2023
ATEEZ Break Down Their Favorite Snacks | Snacked
News

ATEEZ Break Down Their Favorite Snacks | Snacked

December 12, 2023
Next Post
Kevin Hart and Wesley Snipes Star in New Trailer for Netflix Drama ‘True Story’

Kevin Hart and Wesley Snipes Star in New Trailer for Netflix Drama ‘True Story’

  • Media and Podcast Sponsorships
Text Us: (702) 763 - FNGR

© 2022 For No Good Reason. All Rights Reserved.

No Result
View All Result
  • Home
  • Featured Guests
  • Need Advice
  • Playlist of the Week

© 2022 For No Good Reason. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In